High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes

Tatiana Koudriavtseva, Giovanna D’Agosto, Chiara Mandoj, Isabella Sperduti, Paola Cordiali-Fei

Research output: Contribution to journalArticlepeer-review

Abstract

The exact prevalence and pathogenic role of antiphospholipid antibodies (aPL) in multiple sclerosis (MS) remain unclear. This observational laboratory-blinded study evaluated the rate of aPL positivity in healthy controls and MS patients in different disease phases to recognize their frequency and possible pathogenic meaning. Reactivity for anti-cardiolipin, anti-β2 glycoprotein I, anti-prothrombin, anti-annexin V (IgG and IgM) was studied by enzyme immunoassays in 60 healthy controls and 100 consecutive MS patients [58 relapsing–remitting (RR) patients in remission, 26 RR patients in relapse, and 16 secondary progressive patients]. The overall rate of positivity for at least one aPL was significantly higher in MS patients compared to controls (32 % vs. 7 %, respectively, p 

Original languageEnglish
Pages (from-to)1737-1741
Number of pages5
JournalNeurological Sciences
Volume35
Issue number11
DOIs
Publication statusPublished - 2014

Keywords

  • Antiphospholipid antibodies
  • Beta 2-glycoprotein-I
  • Multiple Sclerosis
  • Prothrombin
  • Relapse

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Fingerprint

Dive into the research topics of 'High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes'. Together they form a unique fingerprint.

Cite this